Researchers presented the development of a translational pharmacokinetic (PK)/receptor occupancy (RO) model of the tetravalent bispecific antibody (bsAb) CTX-8371 (Compass Therapeutics LLC) with the ...
There were no serious adverse events (SAEs) There were no treatment emergent adverse events leading to discontinuation of AK006 There were no dose limiting toxicities The most common adverse events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback